Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics

Core Insights - The analysis focuses on two biotech companies, Altimmune and Viking Therapeutics, which are developing GLP-1-targeted medicines for obesity, aiming to compete with established products from Eli Lilly and Novo Nordisk [8] Company Analysis Viking Therapeutics - Viking's lead candidate, VK2735, has shown promising results in its phase 2b clinical trial, with participants losing an average of 15.6% of their mass over 48 weeks [7][9] - The company is well-capitalized with $963 million in cash and equivalents, and it has no debt, which positions it favorably for commercialization [20] - Viking's pipeline includes non-GLP-1 programs, providing additional avenues for growth and reducing reliance on a single product [13] Altimmune - Altimmune's lead program is nearing the end of phase 2 trials, with strong interim data suggesting a likely continuation to phase 3 trials [11] - The company has $182 million in cash and equivalents, with total expenses of $89 million, indicating it can sustain operations but may need to raise additional funds for commercialization [22] - Altimmune's candidate may preserve muscle mass during weight loss, which could appeal to specific demographics such as seniors and those with mobility issues [21][18] Market Position - Both companies are positioned to capture market share in the obesity treatment sector, with Viking slightly ahead in terms of market readiness [9][19] - The absence of direct competition for Altimmune in its segments may provide a strategic advantage [12] - The potential for both companies to succeed in their clinical trials and secure regulatory approval in the coming years is high, making them attractive investment opportunities [19]